Australia markets closed

SAVA Jan 2025 45.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
5.450.00 (0.00%)
At close: 11:45AM EDT
Full screen
Previous close5.45
Open5.35
Bid0.00
Ask0.00
Strike45.00
Expiry date2025-01-17
Day's range5.35 - 5.45
Contract rangeN/A
Volume5
Open interest434
  • GlobeNewswire

    Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

    An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials Continue as Planned, Without Modification. Final Clinical Safety Data for Simufilam Are Expected at the Conclusion of the Phase 3 Program. AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced th

  • Simply Wall St.

    Bullish Cassava Sciences Insiders Loaded Up On US$3.12m Of Stock

    Quite a few insiders have dramatically grown their holdings in Cassava Sciences, Inc. ( NASDAQ:SAVA ) over the past 12...

  • GlobeNewswire

    Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference

    AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced plans to present a virtual oral presentation at the International Conference on Alzheimer’s and Parkison’s Disease (AD/PD 2024) taking place in Lisbon, Portugal from March 5-9, 2024. Presentation details Title: Oral Simufilam in Mild-to-moderate Alzheimer’s Disease: Baseline Characteristics in RETHINK and REFOCUS Phase 3 T